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The clinical management and subsequent outcome of 
pediatric and neonatal patients can improve significantly 
with the availability of effective and safe medicines if ap-
propriately investigated in the relevant population [1]. 
This is also the case for neonates treated with hypother-
mia for perinatal asphyxia. However, the vast majority of 
medicines are developed with adult pathophysiology in 
mind and are not guided by neonatal (patho)physiology. 
Drug development is mainly driven by adult indications, 
subsequently tailored or repurposed for use in neonates, 
with exogenous surfactant as the latest but hopefully not 
last example of drug discovery specific to neonates [2].
Since there is level I evidence in support of therapeutic 
hypothermia for asphyxiated neonates (number needed 
to treat: 7, 95% CI 5–10), there is a very active research 
line investigating add-on pharmacotherapy to further 
improve this outcome [2, 3]. After an unstructured search 
on the European Medicines Agency (EMA) website, al-
lopurinol, Argon, Xenon, VH-N439, cannabidiol, 2-imi-
nobiotin, melatonin, and erythropoietin development 
plans were retrieved (besides stem cell-related approach-
es) as orphan development programs for this indication. 
In the setting of an orphan indication, with the need for 
immediate neonatal intervention and, as a consequence, 
a very high logistic burden to conduct this kind of studies, 
we need to generate as much as possible add-on knowl-
edge from the currently available fragmented data on 
(patho)physiological changes in organ function and blood 
flow, or drug-specific pharmacokinetics to make these 
studies more feasible and explore the underlying mecha-
nisms in this specific clinical setting. 
Using an opportunistic sampling approach and non-
linear mixed effects modeling techniques [4], Favié et al. 
[5] quantified the impact of phenobarbital co-adminis-
tration on midazolam clearance (factor 2.3 higher, 95% 
CI 1.9–2.9) in neonates undergoing therapeutic hy-
pothermia, while the subsequent 1′-hydroxymidazolam 
clearance (glucuronidation and renal elimination) was 
reduced (–25%) by hypothermia. Based on our experi-
ence and expertise in perinatal pharmacology, we would 
like to draw the attention of clinicians and clinician sci-
entists to the relevance of this new information for clini-
cal management and neonatal drug development.
As mentioned by the authors, the consequence of these 
findings is that midazolam clearance in neonates is al-
ready driven to a clinically relevant extent by phenobar-
bital co-exposure, indicating the capacity of this fre-
quently used drug to induce cytochrome P450 (CYP)3A 
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activity already early in life. Similar patterns can be an-
ticipated for other drugs when co-administered with phe-
nobarbital, such as sildenafil (co-occurrence pulmonary 
hypertension) or fentanyl (narcotic) [6, 7]. For all these 
drugs, a fast postnatal age-driven maturational increase 
in clearance is described, and it is reasonable to anticipate 
that this pattern will be further enhanced when pheno-
barbital is co-administered [6, 7]. 
The other way around, clinicians should also be aware 
that shifts in antiepileptic drug (AED) prescription prac-
tices may also result in additional effects because of shifts 
in drug utilization may result in shifts in the occurrence 
of drug-drug interactions. Using the Pediatrix database 
on medication use in neonates, Ahmad et al. [8] reported 
that neonates with seizures are still almost all exposed to 
phenobarbital with a decrease (15–11%) in the use of phe-
nytoin mirrored by a significant increase (1.4–14%) in 
levetiracetam prescription over time (2005 to 2014) [9]. 
Some authors advocate the use of other AEDs like leveti-
racetam as first-line AED in neonates [5, 10]. If so, a sim-
ilar dosing (mg/kg) of benzodiazepines as second-line 
AED will result in higher exposure to benzodiazepines in 
levetiracetam cases because of the absence of phenobar-
bital-related induction. 
Besides the clinical relevance, this detailed PK analysis 
also unveiled changes in metabolic and elimination path-
ways, and such information is important beyond drug-
specific observations: neonatal pharmacology reflects de-
velopmental (patho)physiology [11]. Variability is the 
core business of neonatal pharmacology because devel-
opment and growth (weight gain) are most prominent in 
early infancy, while PK are further affected by nonmatu-
rational covariates such as polymorphisms or environ-
mental (drug-drug, drug-nutrition, drug-treatment mo-
dalities, disease, but also therapeutic hypothermia + peri-
natal asphyxia) factors [2, 11].
Physiologically based PK (PBPK) techniques provide 
a potent systematic approach to make the most of already 
acquired knowledge (physiology, system knowledge) to 
capture the variability, to adapt dosing, or to assist in the 
trial design in neonates [12, 13]. PBPK hereby integrates 
different types of information, such as clinical data and in 
silico, in vitro, and in vivo observations to predict drug 
exposure over time. PBPK hereby explicitly discriminates 
between population physiological properties (system pa-
rameters such as cardiac output, organ perfusion or blood 
flow, renal function, liver size, weight, plasma protein, 
different between and within populations) and drug-spe-
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Fig. 1. Development and validation of PBPK models, specific to neonates undergoing therapeutic hypothermia. 
Such a workflow necessitates – besides drug specific physicochemical input – data sharing and availability of in 
vivo PK data in the population of interest (neonates,*), but also data on the disease state (asphyxia,**) and on the 
impact of hypothermia (***).
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cific (chemical, pH, solubility) properties, not different 
between populations (Fig. 1). 
Progress in this field, however, necessitates contribu-
tions of clinicians by generating datasets on PK and mat-
urational physiology to use these datasets to refine PBPK 
model predictions. This necessitates data sharing and 
availability of in vivo PK data in the population of interest 
(newborns, *), data on disease state (asphyxia, **), and the 
impact of hypothermia itself (***), and this is exactly why 
clinicians should become aware of the relevance of such 
data beyond drug-specific relevance. Once developed and 
validated, such PBPK tools may indeed be instrumental 
to assure that studies on pharmacological interventions 
become much more feasible. Using this approach, it has 
applications in first-in-adult/child, first-in-newborn, or 
first-in the-newborn-treated-with-hypothermia drug de-
velopment. The final intention is to generate dosing rec-
ommendations, or alternatively, simulations to subse-
quently conduct PK studies, also in this specific hypo-
thermia setting.
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